Spark, Sideris raise Series A funds after 3Q venture capital sinks
This article was originally published in Scrip
Executive Summary
Total venture capital dollars invested in biotechnology firms sank 39% between the second and third quarters, but the last three months of 2013 could make up lost ground if a mid-October surge in private equity for drug developers, including Spark Therapeutics and Sideris Pharmaceuticals, continues until the end of the fourth quarter.